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Background/aim: The NoSAS score is a new tool for the identification of high-risk patients for sleep-disordered breathing (SDB). The
aim of this study was to validate the NoSAS score in a sleep clinical population in Turkey and compare its performance with the Epworth
Sleepiness Scale (ESS), STOP-Bang, and Berlin questionnaires for high-risk SDB.
Materials and methods: This was a retrospective study. Patients who had a full-night PSG examination between 01.03.2017 and
01.01.2018 at the sleep center of our hospital were included in the study. Demographic characteristics, anthropometrics measurements,
ESS, STOP-Bang, and Berlin scores were collected from the existing data of the patients. The NoSAS score was subsequently calculated
based on available data. Predictive parameters for each screening questionnaires were calculated to compare the discriminative power
of those for high-risk SDB.
Results: A total of 450 patients were included in the study. The sensitivity, specificity, PPV, and NPV of the NoSAS score were 81%,
51.2%, 88.2%, and 37.5% for an AHI (apnea–hypopnea index) ≥ 5 event/h and 84.5%, 38.2%, 66%, and 63.4% for an AHI ≥ 15 event/h,
respectively. AUC percentages for the NoSAS score, STOP-Bang questionnaire, Berlin questionnaire, and ESS were 0.740, 0.737, 0.626,
and 0.571 for an AHI ≥ 5 events/h and 0.715, 0.704, 0.574, and 0.621 for an AHI ≥ 30 events/h. The NoSAS score had a false negative
rate of 2.9% for severe SDB.
Conclusion: The NoSAS score had a good degree of differentiation for SDB and can be used as an easily applicable, subjective, and
effective screening tool in a sleep clinical population in Turkey. Not only in moderate to severe SDB but also in mild SDB, the NoSAS
score performed better than the other 3 screening tools.
Key words: NoSAS score, sleep-disordered breathing, STOP-Bang, Berlin questionnaire

1. Introduction
Sleep-disordered breathing (SDB) is a highly prevalent
and grossly underrecognized disease that is characterized
by repetitive collapse of the upper airway during sleep.
It has been suggested that 34% of men aged 30–70 and
17% of women aged 30–70 have SDB [1]. It has been
estimated that up to 80% of individuals with moderate to
severe SDB may remain undiagnosed and, furthermore,
untreated [2]. Patients with untreated sleep-disordered
breathing are at increased risk of hypertension, stroke,
heart failure, diabetes, car accidents, and depression [3].
Currently, the gold standard for diagnosing SDB is a fullnight polysomnography (PSG). However, the procedure
is time-consuming, expensive, complex, and relatively

inaccessible; it also requires technical personnel. Long
waiting periods for sleep studies are still an important
problem for the diagnosis of OSA, even in developed
countries [4]. Screening questionnaires are simple, easy to
use, and low-cost tools that can be used to prioritize the
patients eligible for PSG. Different clinical questionnaires
have been previously proposed as screening tools for SDB
[5]. The STOP-Bang questionnaire, Berlin questionnaire,
and Epworth Sleepiness Scale (ESS) are the most
commonly used screening tools for SDB [6]. ESS was
originally designed to evaluate daytime sleepiness [7]. The
STOP-Bang and Berlin questionnaires were developed
using less sensitive technology than those currently
used. Considering these technical differences and their
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effects on the diagnosis and perceived prevalence of SDB,
Marti-Soler et al. developed a new screening tool for SDB
in a cohort study of 2121 subjects in a Swiss population
(HypnoLaus cohort) using current standards as a
reference. The NoSAS score was also validated by another
cohort in Brazil (EPISONO) that included 1042 subjects
to ensure its reliability in different populations. The results
of this study revealed that the NoSAS score can be used as
simple, efficient, and easy to implement score to identify
individuals at risk of SDB [8]. However, different clinical
populations may present different results. As a result,
the effectiveness of the NoSAS score in different clinical
populations should be evaluated.
The purpose of the current study was to validate the
NoSAS score in a sleep clinical population in Turkey and
compare its performance with the STOP-Bang and Berlin
questionnaires and with the Epworth Sleepiness Scale to
predict high-risk patients for SDB.
2.Material and methods
2.1. Subjects
This study was a retrospective analysis of patients who
had already had a full-night PSG examination between
01.03.2017 and 01.01.2018 at the sleep center of the
University of Health Science, Dr. Suat Seren Training
and Research Hospital. All patients were suspected of
having SDB. The criteria for inclusion were as follows:
(1) over 18 years of age; (2) no previous diagnosis and
treatment of SDB; (3) completed anthropometric data
regarding ESS, STOP-Bang, and Berlin Questionnaires in
a sleep laboratory; and (4) a sleep efficacy ≥60%. Those
who did not meet these criteria were excluded from the
study. Additionally, patients who had an active psychiatric
disorder, a history of brain tumors, epilepsy, or had used
benzodiazepine were also excluded from the study.
In our study, basic demographics (e.g., age and sex),
anthropometric measurements (height, weight, BMI, and
neck circumference), ESS, STOP-Bang questionnaire,
Berlin questionnaire, and PSG parameters (apnea–
hypopnea index (AHI), oxygen desaturation index (ODI),
and sleep efficacy) were collected from the existing data
of the patients. The comorbidities of all patients were
also recorded. The NoSAS score was obtained using the
existing data of the patients.
2.2. Screening questionnaires
The ESS is an eight-item questionnaire; it uses a four-point
Likert response format (0–3), and the score ranges from
0 to 24. An ESS score of ≥10 indicates excessive daytime
sleepiness and high risk for OSA [7].
The Berlin questionnaire incorporates 11 questions
organized into 3 categories. The first category includes
5 questions about snoring, the 2nd category includes 3
questions about daytime sleepiness and fatigue, and the
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last category includes information about the history of
hypertension and body mass index (BMI). The overall
Berlin score was determined from the responses to these
3 categories: the 1st and 2nd categories are considered
positive if the responses indicate frequent symptoms
(>3–4 times/week) on 2 or more questionnaire items, and
the 3rd category is considered positive if there is a history
of hypertension or a BMI >30 kg/m2. Patients who had a
positive score on 2 or more categories were classified as
being at high-risk for OSA [9].
The STOP-Bang questionnaire includes 8 dichotomous
(yes/no) questions, 4 of which are subjective (STOP:
snoring, tiredness, observed apnea, and high blood
pressure) and 4 of which are demographic (Bang: BMI >35
kg/m2, age >50 years, neck circumference >40 cm, male
sex). The total score ranges from 0–8. Answering ‘yes’ to
3 or more question places the patient at high risk for SDB
[10]. We used a valid Turkish language version of the 3
questionnaires [11–13] .
The NoSAS score is a new screening tool. This score,
which ranges from 0–17, allocates 4 points for having a
neck circumference of more than 40 cm, 3 points for
having a BMI of 25 kg/m² to less than 30 kg/m² or 5 points
for having a BMI of 30 kg/m² or more, 2 points for snoring,
4 points for being older than 55 years of age, and 2 points
for being male. An NoSAS score of 8 or higher is indicative
of being at high risk for SDB [8].
2.3. In-laboratory polysomnography
The diagnosis of OSA was made using an in-lab
polysomnographic examination. Electroencephalography,
electrooculography, electromyography of the chin
and the leg (anterior tibialis), electrocardiography,
oxygen saturation (from fingertips), respiratory effort
(thoracic, abdominal) and air flow (nasal pressure
transducer and oronasal thermistor), body position,
and tracheal microphone were recorded with the Comet
Grass Telefactor version 4.5.3 (Comet Group, Flamatt,
Switzerland). Polysomnography recordings were analyzed
by a physician experienced in sleep disorders using TWin
EEG/PSG Software. Scoring of the sleep and respiratory
events were done according to the criteria of the AASM
manual version 2.3 [14]. The AHI was defined as the
number of apnea and hypopnea events per hour. The
diagnosis of OSA was defined by AHI. The severity of SDB
was categorized as follows: mild (5 ≤ AHI < 15 events/h),
moderate (15 ≤ AHI < 30 events/h), and severe (AHI ≥ 30
events/h).
2.4. Statistical analysis
Statistical analyses were performed using IBM-SPSS version
25.0 (IBM Corp., Armonk, NY, USA). The demographic
data was presented with descriptive statistics. Numerical
data were given as the mean ± standard deviation (SD),
and frequency data were given as number and percentage
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(%). The concordance of numerical variables with normal
distribution was evaluated with the Shapiro–Wilk test.
For normal distributions, a Student’s t-test was used to
compare the 2 groups. Cross tabulation was used for
categorical data and chi-square analysis was performed.
PSG was considered as the gold standard and the sensitivity,
specificity, positive predictive values (PPV), and negative
predictive values (NPV) of the ESS, Berlin, and STOP-Bang
questionnaires, along with the NoSAS score according to
specific cut-off values, were calculated. Receiver-operating
characteristic (ROC) curves were constructed to assess
the ESS, Berlin, STOP-Bang questionnaires, and the
NoSAS score regarding their likelihood to predict highrisk for OSA. Correlation between the questionnaires was
analyzed by Pearson’s correlation coefficient. All tests were
two-sided and statistical significance was assumed when
P < 0.05.
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional and/or national research committee
and with the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards. The study
was approved by the local research ethics committee
(23.10.2018, Number: 11688).
3. Results
A total of 450 patients were included in the study (Figure
1). Approximately 66.7% of the study population was male

and 33.3% females. The mean age of the subjects was 50.6 ±
11.3. Demographic and anthropometric characteristics of
the study population are presented in Table 1. According
to the PSG results: 104 patients (23.1%) had mild SDB,
122 patients (26.6%) had moderate SDB, and 142 patients
(31.5%) had severe SDB.
The effectiveness of the NoSAS score as a screening
tool for SDB was evaluated using the different cut off
points of AHI. Table 2 shows the predictive parameters of
the NoSAS score, STOP-Bang questionnaire, and Berlin
questionnaire for AHI cutoffs of 5, 10, 15, 20, 25, and 30
events/h. The sensitivity of the NoSAS score increases as the
AHI increases. For an AHI ≥ 5, the sensitivity, specificity,
and PPV and NPV of the NoSAS score were 81%, 51.2%,
88.2%, and 37.5%, respectively. On the basis of its ability to
discriminate subjects with clinically significant SDB (i.e. an
AHI of ≥15 events/h), the sensitivity, specificity, and PPV
and NPV of the NoSAS score was 84.5%, 38.2%, 66%, and
63.4%, respectively. The STOP-Bang questionnaire had the
highest sensitivity for all AHI cut off points but also had the
lowest specificity. The Berlin questionnaire demonstrated
similar results to the STOP-Bang questionnaire. For an
AHI of ≥15 events/h, the sensitivity, specificity, and PPV
and NPV of the ESS was 53.8%, 59.1%, 65.1%, and 47.4%,
respectively.
To compare the performance of the questionnaires for
predicting SDB, ROC curves were constructed. We found
that the AUC for the NoSAS score was larger than that of

709 subjects
39 review PSG after treatment
13 refused to conduct PSG
657 subjects
87 incomplete questionnaires
24 missing anthropometric data
data
546 subjects
68 sleep efficacy <60%
28 other disease&drug use
450 subjects included
Figure 1. Flow diagram. PSG: Polysomnography.

PSG; Polysomnography.
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Table 1. Baseline characteristics of the study population (n: 450).
AHI < 5 events/h

AHI ≥ 5 events/h

Number (%)

82 (18.2)

368 (81.7)

Male sex, N (%)

38 (46.3)

262 (87.3)

<0.001

Age, year

44.3 ± 11.5

51.3 ± 11.3

<0.001

BMI, kg/m

29.0 ± 5.2

32.1 ± 5.9

<0.001

Neck circumference, cm

39.2 ± 2.95

41.5 ± 3.1

<0.001

Smoker, N (%)

38 (46.3)

153 (41.6)

0.430

Snoring, N (%)

73 (89)

353 (95,9)

0.012

Witnessed apnea ,N (%)

56 (68.3)

309 (84)

0.001

Daytime sleepiness, N (%)

71 (86.6)

320 (87)

0.928

NoSAS

7.9 ± 4.0

11.4 ± 3.3

<0.001

STOP-Bang

3.9 ± 1.4

5.2 ± 1.3

<0.001

Berlin

2.0 ± 0.8

2.4 ± 0.6

<0.001

ESS

8.3 ± 5.4

9.9 ± 6.1

0.031

Hypertension, N (%)

21 (25.6)

142 (38.6)

0.027

Diabetes Mellitus, N (%)

12 (14.6)

97 (38.6)

0.025

2

P value

Data is depicted as mean ± SD or number (percentage).
BMI: body mass index; ESS: Epworth sleepiness scale.
Table 2. Predictive parameters of the NoSAS score and STOP-Bang and Berlin questionnaires for AHI cut offs
of 5, 10, 15, 20, 25, and 30 events/h.
AHI≥5

AHI≥10

AHI≥15

AHI≥20

AHI≥25

AHI≥30

Sensitivity (%)

81

83

84.5

86

87.3

90.8

Specificity (%)

51.2

42.8

38.2

35.5

33.1

32.1

PPV(%)

88.2

76.6

66

56.5

46.7

38.2

NPV (%)

37.5

52.7

63.4

72.3

79.5

88.4

Sensitivity (%)

97.8

97.8

98.5

98.6

98.9

98.6

Specificity (%)

15.9

10.1

9.1

7.9

7.1

6.2

PPV (%)

83.9

71.1

60.6

51

41.7

32.6

NPV (%)

61.9

66.7

81

85.7

90.5

90.5

Sensitivity (%)

89.9

89.4

88.6

90.1

91.2

93.7

Specificity (%)

26.8

18.8

15.6

16.2

16

16.2

PPV (%)

84.7

71.4

59.8

51.2

42.2

34

NPV (%)

37.3

44.1

49.2

62.7

72.9

84.7

NoSAS score

STOP-Bang

Berlin

AHI: apnea–hypopnea index; PPV: positive predictive value; NPV: negative predictive value.

the 3 remaining questionnaires for all AHI cutoff points
(Table 3). For an AHI ≥ 5 events/h, the NoSAS score had
the largest AUC (0.740). It was followed by the STOP-Bang
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questionnaire (AUC: 0.737 for an AHI ≥ 5 event/h). The
AUC of the ESS for an AHI ≥ 5 events/h was the lowest
(Figure 2). For the other cut off points of AHI except an
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Table 3. Performance of the NoSAS score compared with STOP-Bang, Berlin, and ESS scores (AUC).
Questionnaire

AHI≥5

AHI≥10

AHI≥15

AHI≥20

AHI≥25

AHI≥30

NoSAS

0.740

0.703

0.691

0.692

0.690

0.715

STOP-Bang

0.737

0.692

0.679

0.676

0.665

0.704

Berlin

0.626

0.569

0.538

0.539

0.532

0.574

ESS

0.571

0.576

0.600

0.587

0.607

0.621

Data are presented as values. AUC: area under the curve; AHI: apnea–hypopnea index; ESS: Epworth sleepiness
score.

Figure 2. ROC curves of the 4 screening tools for an AHI ≥ 5 event/h. AHI: apnea–
hypopnea index.

AHI ≥ 5 event/h, the Berlin score has the lowest AUC
(0.569, 0.538, 0.539, 0.532, and 0.574 for AHIs ≥ 10, 15, 20,
25, 30, respectively).
Overall, the NoSAS score correctly classified 298 of the
368 participants (81%) for an AHI ≥ 5 event/h and 223 of
264 participants (84.5%) for an AHI ≥ 15 event/h. The false
negative rate for the NoSAS score was 9.1% for an AHI ≥
15 event/h. When we compared the false negative group
with the true positive group for NoSAS at the cut off point
of AHI ≥ 15 event/h, there was a statistically significant
difference regarding age, BMI, neck circumference, and
for the male sex. In addition to this, significant differences
were found between these 2 groups in terms of AHI and
ODI (Table 4). The NoSAS score had a false negative rate
of 2.9% for patients with severe SDB.
The discriminative power of the NoSAS score was also
evaluated considering differences in sex. The sensitivity of
the NoSAS score was higher in male subjects than in those

of female for AHI cut off points of 5, 15, and 30 events/h
(87.4%, 88.7%, and 93.6%, respectively). However,
specificity of the NoSAS score was better in females than
in males for all AHI cut off points (Table 5).
The Pearson correlation coefficient between NoSAS
and STOP-Bang and NoSAS and Berlin was 0.714 and
0.316, respectively (P = 0.01). The correlation coefficient
was not significant between NoSAS and ESS (r = 0.054;
P > 0.05). Additionally, the NoSAS score was evaluated
with AHI and ODI and described with scatter plot figures.
(Figure 3A shows the scatter plot figure with NoSAS and
AHI and Figure 3B shows the scatter plot figure with
NoSAS and ODI).
4. Discussion
Sleep-disordered breathing is a major challenge for
healthcare systems throughout the world [15]. To prevent
the adverse outcomes of SDB, it is important to identify
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Table 4. Comparison of the false negative and the true positive patient groups for the NoSAS score.
False negative group (n: 41)

True positive group (n: 223)

P value

45.8 ± 7.9

53.1 ± 12.0

<0.001

BMI, kg/m

29.2 ± 4.4

33.3 ± 6.30

<0.001

Neck circumference, cm

38.5 ± 1.5

42.5 ± 3.12

<0.001

Male sex (%)

53.7

77.6

0.001

Snoring (%)

95.1

97.3

0.453

AHI, event/h

31.1 ± 16.9

41.7 ± 22

0.002

ODI

47.7 ± 46.0

61.2 ± 46.7

<0.001

Age, year
2

Data is depicted as mean ± SD or number (percentage). BMI: body mass index; AHI: apnea–hypopnea index;
ODI: oxygen desaturation index.
Table 5. Predictive parameters for the NoSAS score for SDB, considering differences in sex.
Male

Female

AHI≥5

AHI≥15

AHI≥30

AHI≥5

AHI≥15

AHI≥30

Sensitivity(%)

87.4

88.7

93.6

65.1

72.5

81.8

Specificity(%)

28.9

21

19.4

70.5

60.5

53

PPV(%)

89.5

67.6

39.8

84.1

61

32.9

NPV(%)

25

50

84.1

45.6

72.1

91.2

SDB: sleep disordered breathing; PPV: positive predictive value; NPV: negative predictive value.

the high-risk patients for SDB [4]. Among the screening
questionnaires developed for this purpose, the NoSAS
score seems to be the most appropriate one for screening
high-risk patients for SDB in a sleep clinical population.
In this study, the NoSAS score demonstrated the largest
AUC compared to the STOP-Bang, Berlin, and Epworth
Sleepiness Scale for all cut off points of AHI. The NoSAS
score is the best sensitivity–specificity compromise,
allowing for the reductions in the number of unnecessary
PSG recordings and the number of missed diagnoses of
SDB.
Using an AHI cut off of ≥20 event/h, we found that
the sensitivity of the NoSAS score was higher (86%) than
that reported in the HypnoLaus (79%), EPISONA (85%),
Chinese (74.8%), and Asian (69.4%) cohorts [8,16,17]. In
the HypnoLaus, EPISONA, and Chinese cohorts, it was
discussed that the NoSAS score had a better performance
than the STOP-Bang and Berlin questionnaires. Clinically
significant SDB is defined as an AHI ≥ 20 event/h in these
cohorts. In the Asian population, Tan A et al. found that
the sensitivity of the NoSAS score was lower than that
reported in the HypnoLaus and EPISONA cohorts and
stated that the NoSAS score had a similar performance to
the STOP-Bang and Berlin questionnaires [17]. In terms
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of specificity, our results represented the lowest levels
compared to the HypnoLaus, EPISONA, Chinese, and
Asian cohorts. However, when we compared the NoSAS
score with the STOP-Bang and Berlin questionnaires
in our population—although it is not perfect—it stands
out due to its having a higher specificity than the other
questionnaires (51.6%, 15,9%, and 26.8%, respectively for
an AHI ≥ 5 event/h). The sensitivities of the STOP-Bang
and the Berlin questionnaires were high in this study,
but their specificities were rather unsatisfactory. The low
specificity of the questionnaires may result in unnecessary
sleep studies and have been documented in similar
population samples [18,19]. The fact that the NoSAS score
consists of objective parameters may also have played
a role in its having a higher specificity than the other
questionnaires in our population. Additionally, containing
any subjective parameter except for snoring makes the
NoSAS score more convenient for clinicians to use [20].
We also compared the discriminative power of the
screening tools, and it was found that the diagnostic
performance of the NoSAS score was better than the other
3 screening questionnaires. The AUC for an AHI ≥ 5 was
0.740, and this was the largest AUC of all AHI cut offs.
The STOP-Bang questionnaire demonstrated a similar but
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Figure 3. (A) Scatter plot figure with NoSAS and AHI; (B) Scatter plot figure with NoSAS and ODI. AHI: apnea–hypopnea index;
ODI: oxygen desaturation index.

lower AUC for an AHI ≥ 5 compared to the NoSAS score.
In the Chinese cohort study performed in a sleep clinic
population, the AUC of the Berlin questionnaire for an AHI
≥ 5 and AHI ≥ 10 was higher than that of NoSAS. However,
the NoSAS score resulted in a better performance than the
Berlin questionnaire for the other cut offs of AHI. In our
study, the Berlin Questionnaire was the worst performing

questionnaire in terms of AUC at an AHI ≥ 10 events/h.
The Berlin questionnaire is complex and not entirely
consistent with the actual situation in Turkey, for example
when looking at questions related to falling asleep while
driving. As reported in the study conducted by Peng et al.,
patients cannot answer the questionnaire if they don’t have
driving experience, and this leads to the low feasibility of
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completion and poor accuracy in such scales. A previously
mentioned study conducted in a sleep clinic population,
the NoSAS score had the largest AUC (0.734) for an AHI
≥ 5 [20]. When studies in sleep clinic populations are
evaluated, it can be concluded that the NoSAS score is
a screening questionnaire that can be used not only for
detecting moderate-to-severe SDB but also for detecting
mild SDB in sleep clinic populations. Identification of
mild SDB is as significant as moderate-to-severe SDB.
Previous population studies have provided important
information linking mild SDB with adverse cardiovascular
and metabolic outcomes [21,22]. The sleep hearth health
study also demonstrated a significant worsening of quality
of life in subjects with mild SDB [23]. The accumulating
literature on mild SDB provides clear evidence that mild
SDB can be treated and that such a treatment can lead to
an improvement in adverse health outcomes [24].
It is important not to neglect high-risk patients for SDB
as well as to not perform unnecessary PSG recordings. In
our study, for moderate SDB, the false negative rate of the
NoSAS score was 9.1%, while it was 2.9% for severe SDB.
The false negative rate for severe SDB was similar in the
HypnoLaus cohort study. When the false negative group
and the true positive group are compared in terms of the
NoSAS score, it was observed that patients in the false
negative group were weaker, younger, and had smaller
neck circumferences; also, the number of male patients
in the group was lower. It has been hypothesized that the
sleep disordered breathing of the patients with a false
negative result in the NoSAS score was more likely to be
related to maxillofacial deformities, a high loop gain, or
upper airway muscle control dysfunction than to obesity
[8]. Care should be taken not to ignore this group of
patients, and further examinations should be scheduled
in the event of clinical suspicion. There is no significant
difference between the 2 groups in terms of snoring,
which is the only subjective variable of the NoSAS score.
This suggests that objective criteria are more effective in
forming the true positive group. The false negative group
was made up of milder SDB patients than the true positive
group, and the oxygen desaturation index was lower in this
group.
When the effects of differences in sex on the NoSAS
score were evaluated, it was seen that the sensitivity of
the NoSAS score was better in males than in females.

However, specificity was better in females than in males.
In other words, the NoSAS score was more successful in
the roll-in in males and in the roll-out in females. The fact
that the male sex is a variable of the NoSAS score may have
affected this situation. However, sex as an indicator adds
only 2 points to the overall score. In males, sensitivity was
quite high in all SDB groups (mild, moderate, and severe),
whereas specificity was low. In the study conducted by Mou
J et al., STOP-Bang performance by sex showed extremely
low specificity in males at the cutoff of ≥3, and alternative
models were recommended [25]. Similarly, models can be
developed to increase the specificity in males within the
NoSAS score. In females, the NoSAS score, particularly
for moderate to severe SDB, demonstrated good results in
terms of both sensitivity and specificity. With increasing
obesity rates worldwide, the incidence of SDB is increasing
in women as well as in men. In a study conducted in
Turkey, the incidence of high-risk SDB has been found to
be higher in women than in men [26]. To our knowledge,
this is the first study that evaluates the effects of differences
in sex on the NoSAS score.
Our study also has some limitations. As one of the
aims of this study was to validate the NoSAS score in a
sleep clinical population, we retrospectively analyzed
the value of the NoSAS score in our sleep center. The
use of retrospective analysis to validate a screening tool
is less ideal than a prospective study. However, this is an
observational study. All of the data such as ESS, the Berlin
and STOP-Bang scores, and biometric measurements
were collected before the PSG recording was initiated. In
addition, although our sleep center also provides services
to patients from provinces other than İzmir, this was a
single center study based on a specific Turkish population.
In conclusion, the NoSAS score performed better than
the ESS and Berlin and STOP-Bang questionnaires in its
identification of high-risk patients for SDB. The NoSAS
score performed better than the other 3 screening tools,
not only in moderate to severe SDB but also in mild SDB.
It is an easily applicable, reliable, and subjective screening
tool that can be effectively used in a sleep clinic population.
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